$1.19
8.18% yesterday
Nasdaq, Nov 25, 09:48 pm CET
ISIN
US4525EP1011
Symbol
IMUX
Sector
Industry

Immunic, Inc. Stock price

$1.18
-0.21 15.11% 1M
-0.07 5.60% 6M
-0.32 21.33% YTD
+0.01 0.85% 1Y
-8.01 87.16% 3Y
-5.82 83.14% 5Y
-786.42 99.85% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.08 7.27%
ISIN
US4525EP1011
Symbol
IMUX
Sector
Industry

Key metrics

Market capitalization $106.29m
Enterprise Value $48.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.58
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-95.80m
Free Cash Flow (TTM) Free Cash Flow $-76.26m
Cash position $59.07m
EPS (TTM) EPS $-1.24
P/E forward negative
Short interest 5.04%
Show more

Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Immunic, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Immunic, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Immunic, Inc. forecast:

Buy
100%

Financial data from Immunic, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.12 0.12
9% 9%
-
-0.12 -0.12
9% 9%
-
- Selling and Administrative Expenses 18 18
17% 17%
-
- Research and Development Expense 78 78
8% 8%
-
-96 -96
4% 4%
-
- Depreciation and Amortization 0.12 0.12
9% 9%
-
EBIT (Operating Income) EBIT -96 -96
4% 4%
-
Net Profit -97 -97
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunic, Inc. Stock News

Neutral
PRNewsWire
about one hour ago
NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024, at 11:30 am ET, during the P...
Positive
Proactive Investors
10 days ago
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr. Andreas Muehler talked with Proactive about the publication of the company's Phase 1 and Phase 1b clinical trial results for IMU-856 in The Lancet Gastroenterology & Hepatology.
Positive
Proactive Investors
13 days ago
Immunic Inc (NASDAQ:IMUX) announced that data from its phase 1/1b clinical trial for IMU-856, a small molecule targeting SIRT6, has been published in The Lancet Gastroenterology & Hepatology. The study, led by Dr James Daveson, a gastroenterologist with Wesley Research Institute in Australia, evaluated IMU-856's safety and efficacy in patients with celiac disease.
More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office United States
CEO Daniel Vitt
Employees 77
Founded 2003
Website imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today